{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:48:41Z","timestamp":1793040521635,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Special fund project for clinical research of Qingyuan People's Hospital","award":["QYRYCRC2023006"],"award-info":[{"award-number":["QYRYCRC2023006"]}]},{"name":"Special fund project for clinical research of Qingyuan People's Hospital","award":["QYRYCRC2023006"],"award-info":[{"award-number":["QYRYCRC2023006"]}]},{"name":"Special fund project for clinical research of Qingyuan People's Hospital","award":["QYRYCRC2023006"],"award-info":[{"award-number":["QYRYCRC2023006"]}]},{"name":"Special fund project for clinical research of Qingyuan People's Hospital","award":["QYRYCRC2023006"],"award-info":[{"award-number":["QYRYCRC2023006"]}]},{"name":"Special fund project for clinical research of Qingyuan People's Hospital","award":["QYRYCRC2023006"],"award-info":[{"award-number":["QYRYCRC2023006"]}]},{"name":"Special fund project for clinical research of Qingyuan People's Hospital","award":["QYRYCRC2023006"],"award-info":[{"award-number":["QYRYCRC2023006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Emerging evidence supports cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian cancer, yet its efficacy in other malignancies, such as gastric and colorectal cancers, remains uncertain. This meta-analysis evaluates survival outcomes in patients with advanced or metastatic ovarian, colorectal, and gastric cancers treated with CRS and multimodal therapies (e.g., HIPEC, extensive intraoperative peritoneal lavage (EIPL), systemic chemotherapy, immunotherapy, targeted therapy) versus CRS alone or with control-based regimens, focusing on the applicability of these treatments to these specific cancers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We systematically searched PubMed, EMBASE, Web of Science, the Cochrane Library, and the abstracts of the European Society of Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO) congresses up to April 21, 2025, for randomized trials published in English. The primary outcomes were overall survival (OS) and progression-free survival (PFS); secondary outcomes included mortality, adverse events, and 3- and 5-year OS rates. Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled using fixed- or random-effects models, depending on heterogeneity (I\u00b2).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Findings<\/jats:title>\n            <jats:p>From 16,064 records, 13 studies (<jats:italic>n<\/jats:italic>\u2009=\u20093,925 patients, control group\u2009=\u20091,894, experimental group\u2009=\u20092,031) met inclusion criteria. The experimental group significantly improved OS (HR: 0.86, 95% CI: 0.77 \u2013 0.95, <jats:italic>P<\/jats:italic>\u2009=\u20090.003, I\u00b2\u2009=\u200922%, <jats:italic>P<\/jats:italic>\u2009=\u20090.26) and PFS (HR: 0.67, 95% CI: 0.50 \u2013 0.90, <jats:italic>P<\/jats:italic>\u2009=\u20090.009, I\u00b2\u2009=\u200983%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) compared to the control group. Subgroup analyses highlighted heterogeneity in PFS benefits, with recent trials (published in or after 2023) showing more potent effects (HR: 0.53, 95% CI: 0.44 \u2013 0.64, <jats:italic>P<\/jats:italic> &lt; 0.001). Mortality reduction favored the experimental group (risk ratio (RR): 0.86, 95% CI: 0.75 \u2013 0.99, <jats:italic>P<\/jats:italic>\u2009=\u20090.03, I\u00b2\u2009=\u200926%, <jats:italic>P<\/jats:italic>\u2009=\u20090.24), though clinical relevance requires cautious interpretation. The experimental group significantly increased grade 3 or worse adverse events (RR: 1.31, 95% CI: 1.16 \u2013 1.48, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001, I\u00b2\u2009=\u200931%, <jats:italic>P<\/jats:italic>\u2009=\u20090.04), with significant effects driven by digestive system (RR: 1.43, 95% CI: 1.06 \u2013 1.93) and circulatory system (RR: 1.58, 95% CI: 1.07 \u2013 2.32) events. <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interpretation<\/jats:title>\n            <jats:p>CRS combined with multimodal therapies, confers significant survival benefits in advanced ovarian, colorectal, and gastric cancers despite elevated complication risks. These findings support the tailored integration of multimodal strategies in selected patients, highlighting the need for robust randomized trials to validate long-term efficacy and safety.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12957-025-03908-w","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T17:31:12Z","timestamp":1752773472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cytoreductive surgery with multimodal therapies in advanced or metastatic ovarian, colorectal, and gastric cancers: a systematic review and meta-analysis of randomized trials"],"prefix":"10.1186","volume":"23","author":[{"given":"Xiaojun","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huazheng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zisheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"issue":"4","key":"3908_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","volume":"9","author":"S Chen","year":"2023","unstructured":"Chen S, Cao Z, Prettner K, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol. 2023;9(4):465\u201372.","journal-title":"JAMA Oncol"},{"issue":"3","key":"3908_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"3908_CR3","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1016\/S1470-2045(20)30073-5","volume":"21","author":"W Wei","year":"2020","unstructured":"Wei W, Zeng H, Zheng R, et al. Cancer registration in China and its role in cancer prevention and control. Lancet Oncol. 2020;21(7):e342\u20139.","journal-title":"Lancet Oncol"},{"issue":"12","key":"3908_CR4","doi-asserted-by":"publisher","first-page":"e943","DOI":"10.1016\/S2468-2667(23)00211-6","volume":"8","author":"J Qi","year":"2023","unstructured":"Qi J, Li M, Wang L, et al. National and subnational trends in cancer burden in china, 2005-20: an analysis of National mortality surveillance data. Lancet Public Health. 2023;8(12):e943\u201355.","journal-title":"Lancet Public Health"},{"issue":"1","key":"3908_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1053\/j.gastro.2020.02.068","volume":"159","author":"M Arnold","year":"2020","unstructured":"Arnold M, Abnet CC, Neale RE, et al. Global burden of 5 major types of Gastrointestinal Cancer. Gastroenterology. 2020;159(1):335\u2013e4915.","journal-title":"Gastroenterology"},{"issue":"12","key":"3908_CR6","doi-asserted-by":"publisher","first-page":"5889","DOI":"10.7150\/thno.56157","volume":"11","author":"Y Tong","year":"2021","unstructured":"Tong Y, Gao H, Qi Q, et al. High fat diet, gut Microbiome and Gastrointestinal cancer. Theranostics. 2021;11(12):5889\u2013910.","journal-title":"Theranostics"},{"issue":"2","key":"3908_CR7","doi-asserted-by":"publisher","first-page":"188361","DOI":"10.1016\/j.bbcan.2020.188361","volume":"1873","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Wang C, Zhou S. Targeting tumor microenvironment in ovarian cancer: premise and promise. Biochim Biophys Acta Rev Cancer. 2020;1873(2):188361.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"3","key":"3908_CR8","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3908_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","volume":"25","author":"LA Torre","year":"2016","unstructured":"Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer incidence and mortality rates and Trends\u2013An update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16\u201327.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"3908_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian Cancer. N Engl J Med. 2018;378(3):230\u201340.","journal-title":"N Engl J Med"},{"issue":"3","key":"3908_CR11","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris VK, Kennedy EB, Baxter NN, et al. Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol. 2023;41(3):678\u2013700.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3908_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/DCR.0000000000002315","volume":"65","author":"MS Parikh","year":"2022","unstructured":"Parikh MS, Johnson P, Romanes JP, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A systematic review. Dis Colon Rectum. 2022;65(1):16\u201326.","journal-title":"Dis Colon Rectum"},{"issue":"5","key":"3908_CR13","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1097\/IGC.0000000000000696","volume":"26","author":"V D\u2019Hondt","year":"2016","unstructured":"D\u2019Hondt V, Goffin F, Roca L, et al. Interval cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in First-Line treatment for advanced ovarian carcinoma: A feasibility study. Int J Gynecol Cancer. 2016;26(5):912\u20137.","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"3908_CR14","doi-asserted-by":"publisher","first-page":"100586","DOI":"10.1016\/j.esmoop.2022.100586","volume":"7","author":"P Filis","year":"2022","unstructured":"Filis P, Mauri D, Markozannes G, Tolia M, Filis N, Tsilidis K. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials. ESMO Open. 2022;7(5):100586.","journal-title":"ESMO Open"},{"issue":"5","key":"3908_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000528609","volume":"101","author":"S Akturk Esen","year":"2023","unstructured":"Akturk Esen S, Ozgun YM, Hasturk D, et al. Neoadjuvant chemotherapy followed by cytoreductive surgery and HIPEC improves survival in peritoneal metastatic gastric Cancer. Oncology. 2023;101(5):321\u20137.","journal-title":"Oncology"},{"issue":"8","key":"3908_CR16","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jamaoncol.2021.0580","volume":"7","author":"RM van Stein","year":"2021","unstructured":"van Stein RM, Aalbers AGJ, Sonke GS, van Driel WJ. Hyperthermic intraperitoneal chemotherapy for ovarian and colorectal cancer: A review. JAMA Oncol. 2021;7(8):1231\u20138.","journal-title":"JAMA Oncol"},{"key":"3908_CR17","doi-asserted-by":"crossref","unstructured":"Langellotti L, Fiorillo C, D\u2019Annibale G et al. Efficacy of cytoreductive surgery (CRS)\u2009+\u2009HIPEC in gastric Cancer with peritoneal metastasis: systematic review and Meta-Analysis. Cancers (Basel) 2024; 16(10).","DOI":"10.3390\/cancers16101929"},{"issue":"23","key":"3908_CR18","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.18.01688","volume":"37","author":"PE Bonnot","year":"2019","unstructured":"Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric Cancer with peritoneal metastases (CYTO-CHIP study): A propensity score analysis. J Clin Oncol. 2019;37(23):2028\u201340.","journal-title":"J Clin Oncol"},{"issue":"21","key":"3908_CR19","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard D, J\u00e4nne PA, Cheng Y, et al. Osimertinib with or without chemotherapy in EGFR-Mutated advanced NSCLC. N Engl J Med. 2023;389(21):1935\u201348.","journal-title":"N Engl J Med"},{"issue":"16","key":"3908_CR20","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","volume":"391","author":"BC Cho","year":"2024","unstructured":"Cho BC, Lu S, Felip E, et al. Amivantamab plus lazertinib in previously untreated EGFR-Mutated advanced NSCLC. N Engl J Med. 2024;391(16):1486\u201398.","journal-title":"N Engl J Med"},{"issue":"24","key":"3908_CR21","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","volume":"17","author":"MK Parmar","year":"1998","unstructured":"Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815\u201334.","journal-title":"Stat Med"},{"key":"3908_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"3908_CR23","first-page":"Cd011220","volume":"5","author":"SN Hoon","year":"2021","unstructured":"Hoon SN, Lau PK, White AM, Bulsara MK, Banks PD, Redfern AD. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer. Cochrane Database Syst Rev. 2021;5(5):Cd011220.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"3908_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153\u201360.","journal-title":"Evid Based Ment Health"},{"issue":"4","key":"3908_CR25","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","volume":"29","author":"CCP Antonio","year":"2022","unstructured":"Antonio CCP, Alida GG, Elena GG, et al. Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: A phase 3 clinical trial. Ann Surg Oncol. 2022;29(4):2617\u201325.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"3908_CR26","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamasurg.2023.0662","volume":"158","author":"A Arjona-S\u00e1nchez","year":"2023","unstructured":"Arjona-S\u00e1nchez A, Espinosa-Redondo E, Guti\u00e9rrez-Calvo A, et al. Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced Colon cancer: A phase 3 randomized clinical trial. JAMA Surg. 2023;158(7):683\u201391.","journal-title":"JAMA Surg"},{"issue":"10","key":"3908_CR27","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","volume":"24","author":"SL Aronson","year":"2023","unstructured":"Aronson SL, Lopez-Yurda M, Koole SN, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial. Lancet Oncol. 2023;24(10):1109\u201318.","journal-title":"Lancet Oncol"},{"issue":"7","key":"3908_CR28","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1001\/jamasurg.2019.0153","volume":"154","author":"J Guo","year":"2019","unstructured":"Guo J, Xu A, Sun X, et al. Combined surgery and extensive intraoperative peritoneal lavage vs surgery alone for treatment of locally advanced gastric cancer: the SEIPLUS randomized clinical trial. JAMA Surg. 2019;154(7):610\u20136.","journal-title":"JAMA Surg"},{"issue":"9","key":"3908_CR29","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","volume":"9","author":"N Li","year":"2023","unstructured":"Li N, Zhu J, Yin R, et al. Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: A phase 3 randomized clinical trial. JAMA Oncol. 2023;9(9):1230\u20137.","journal-title":"JAMA Oncol"},{"issue":"5","key":"3908_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","volume":"157","author":"MC Lim","year":"2022","unstructured":"Lim MC, Chang SJ, Park B, et al. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: A randomized clinical trial. JAMA Surg. 2022;157(5):374\u201383.","journal-title":"JAMA Surg"},{"issue":"3","key":"3908_CR31","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s10120-011-0027-3","volume":"14","author":"I Miyashiro","year":"2011","unstructured":"Miyashiro I, Furukawa H, Sasako M, et al. Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan clinical oncology group trial JCOG9206-2. Gastric Cancer. 2011;14(3):212\u20138.","journal-title":"Gastric Cancer"},{"issue":"17","key":"3908_CR32","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1200\/JCO.21.00306","volume":"39","author":"KN Moore","year":"2021","unstructured":"Moore KN, Bookman M, Sehouli J, et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: Placebo-Controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39). J Clin Oncol. 2021;39(17):1842\u201355.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3908_CR33","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3908_CR34","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1200\/JCO.22.02867","volume":"42","author":"B Rau","year":"2024","unstructured":"Rau B, Lang H, Koenigsrainer A, et al. Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric Cancer with synchronous peritoneal metastases: the phase III GASTRIPEC-I trial. J Clin Oncol. 2024;42(2):146\u201356.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3908_CR35","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/curroncol31020048","volume":"31","author":"P Villarejo Campos","year":"2024","unstructured":"Villarejo Campos P, S\u00e1nchez Garc\u00eda S, Amo-Salas M, et al. Paclitaxel as HIPEC-Drug after surgical cytoreduction for ovarian peritoneal metastases: A randomized phase III clinical trial (HIPECOVA). Curr Oncol. 2024;31(2):660\u201371.","journal-title":"Curr Oncol"},{"issue":"6","key":"3908_CR36","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","volume":"18","author":"XJ Yang","year":"2011","unstructured":"Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575\u201381.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"3908_CR37","doi-asserted-by":"publisher","first-page":"e2371","DOI":"10.1016\/j.ajog.2021.04.254","volume":"225","author":"BB Albright","year":"2021","unstructured":"Albright BB, Monuszko KA, Kaplan SJ, et al. Primary cytoreductive surgery for advanced stage endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol. 2021;225(3):e2371\u201324.","journal-title":"Am J Obstet Gynecol"},{"key":"3908_CR38","doi-asserted-by":"crossref","unstructured":"Graf W, Ghanipour L, Birgisson H, Cashin PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases from colorectal Cancer-An overview of current status and future perspectives. Cancers (Basel) 2024; 16(2).","DOI":"10.3390\/cancers16020284"},{"key":"3908_CR39","doi-asserted-by":"crossref","unstructured":"Jain AJ, Badgwell BD. Current evidence for the use of HIPEC and cytoreductive surgery in gastric Cancer metastatic to the peritoneum. J Clin Med 2023; 12(20).","DOI":"10.3390\/jcm12206527"},{"key":"3908_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.03.030","volume":"79","author":"J Desiderio","year":"2017","unstructured":"Desiderio J, Chao J, Melstrom L, et al. The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer. 2017;79:1\u201314.","journal-title":"Eur J Cancer"},{"issue":"Suppl 3","key":"3908_CR41","doi-asserted-by":"publisher","first-page":"S758","DOI":"10.1245\/s10434-015-4853-0","volume":"22","author":"L Schaaf","year":"2015","unstructured":"Schaaf L, van der Kuip H, Zopf W, et al. A temperature of 40\u00b0C appears to be a critical threshold for potentiating cytotoxic chemotherapy in vitro and in peritoneal carcinomatosis patients undergoing HIPEC. Ann Surg Oncol. 2015;22(Suppl 3):S758\u201365.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"3908_CR42","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3109\/02656738909140459","volume":"5","author":"K Naito","year":"1989","unstructured":"Naito K, He Q, Skog S, Tribukait B, Andersson L, Hisazumi H. Effects of adriamycin and hyperthermia on cellular uptake of [3H]thymidine and its significance for the incorporation into DNA. Int J Hyperth. 1989;5(3):329\u201340.","journal-title":"Int J Hyperth"},{"key":"3908_CR43","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.bpobgyn.2021.09.002","volume":"78","author":"GE Wood","year":"2022","unstructured":"Wood GE, Ledermann JA. Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2022;78:64\u201373.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"9","key":"3908_CR44","doi-asserted-by":"publisher","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","volume":"20","author":"DK Armstrong","year":"2022","unstructured":"Armstrong DK, Alvarez RD, Backes FJ, et al. NCCN Guidelines\u00ae insights: ovarian cancer, version 3.2022. J Natl Compr Canc Netw. 2022;20(9):972\u201380.","journal-title":"J Natl Compr Canc Netw"},{"key":"3908_CR45","doi-asserted-by":"publisher","first-page":"1131342","DOI":"10.3389\/fphar.2023.1131342","volume":"14","author":"X Huang","year":"2023","unstructured":"Huang X, Li XY, Shan WL, Chen Y, Zhu Q, Xia BR. Targeted therapy and immunotherapy: diamonds in the rough in the treatment of epithelial ovarian cancer. Front Pharmacol. 2023;14:1131342.","journal-title":"Front Pharmacol"},{"issue":"3","key":"3908_CR46","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.ejso.2021.10.013","volume":"48","author":"LCK Wong","year":"2022","unstructured":"Wong LCK, Li Z, Fan Q, et al. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal sarcomatosis-A systematic review and meta-analysis. Eur J Surg Oncol. 2022;48(3):640\u20138.","journal-title":"Eur J Surg Oncol"},{"issue":"11","key":"3908_CR47","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1016\/j.ejso.2021.05.016","volume":"47","author":"S Granieri","year":"2021","unstructured":"Granieri S, Bonomi A, Frassini S, et al. Prognostic impact of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients: A meta-analysis of randomized controlled trials. Eur J Surg Oncol. 2021;47(11):2757\u201367.","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"3908_CR48","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.cell.2024.12.010","volume":"188","author":"L Zhong","year":"2025","unstructured":"Zhong L, Gan L, Wang B, et al. Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients. Cell. 2025;188(4):1119\u2013e3623.","journal-title":"Cell"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03908-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03908-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03908-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T13:54:28Z","timestamp":1757253268000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03908-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3908"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03908-w","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"5 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required due to the use of published data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not available.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"286"}}